PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.

CompletedOBSERVATIONAL
Enrollment

280

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

July 31, 2011

Conditions
HIV Infections
Trial Locations (17)

Unknown

Boehringer Ingelheim Investigational Site 1, Graz

Boehringer Ingelheim Investigational Site 2, Linz

Boehringer Ingelheim Investigational Site 3, Salzburg

Boehringer Ingelheim Investigational Site 4, Vienna

Boehringer Ingelheim Investigational Site 5, Vienna

Boehringer Ingelheim Investigational Site 6, Vienna

Boehringer Ingelheim Investigational Site 7, Wels

Boehringer Ingelheim Investigational Site 8, Bialystok

Boehringer Ingelheim Investigational Site 9, Bydgoszcz

Boehringer Ingelheim Investigational Site 10, Chorzów

Boehringer Ingelheim Investigational Site 11, Gdansk

Boehringer Ingelheim Investigational Site 12, Krakow

Boehringer Ingelheim Investigational Site 13, Lódz

Boehringer Ingelheim Investigational Site 14, Poznan

Boehringer Ingelheim Investigational Site 15, Szczecin

Boehringer Ingelheim Investigational Site 16, Warsaw

Boehringer Ingelheim Investigational Site 17, Wroclaw

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00736502 - PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice. | Biotech Hunter | Biotech Hunter